Trial Profile
A retrospective observational study evaluating safety and efficacy of pirfenidone for treatment of idiopathic pulmonary fibrosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Mar 2017
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Therapeutic Use
- 09 Mar 2017 New trial record
- 01 Feb 2017 Results published in the International Journal of Clinical PharmacyConference: 45th ESCP-NSF International Symposium on Clinical Pharmacy: Clinical Pharmacy Tackling Inequalities and Access to Health Care Norway